Llwytho...
Gemtuzumab Ozogamicin for Treatment of Acute Myeloid Leukemia
INTRODUCTION: Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin. Despite the known clinical efficacy in relapsed/refractory acute myeloid leukemia (AML), GO was withdrawn from the market in 20...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Expert Rev Clin Pharmacol |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6661897/ https://ncbi.nlm.nih.gov/pubmed/29787320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/17512433.2018.1478725 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|